ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · USD

$15.8

+0.37 (+2.4%)· Recorded snapshot

Market cap	777.6M
Net income (ttm)	-164.2M
EPS (ttm)	-$3.70
Shares out	49.3M
Volume	800,609
Beta	1.35

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -164.2M
EPS (ttm): -$3.70
Market cap: 777.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-53.3

P25 n/aP50 n/aP75 n/a

ROIC-35.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AVBP indicators

Market & fundamental data

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001868279
Company name	ArriVent BioPharma, Inc.
Country	United States
Country code	US
CUSIP number	04272N102
Earnings date	2026-11-09
Earnings time	bmo
Employees	77
Employees change	25
Employees growth	48.08%
Enterprise value	$404.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2021
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2024-01-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US04272N1028
Last 10-K release date	2026-03-05
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$777.6M
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$15.77
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AVBP
U.S. state	Pennsylvania
Website	https://arrivent.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-23.45%
FCF / EV yield	-37.6%
FCF yield	-19.31%
Forward EV/Sales	51.58x
Forward P/S	100.44x
P/B ratio	2.03x
Price / tangible book value	2.09x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.1M
ROA	-33.11%
ROCE	-47.96%
ROE	-53.25%
ROIC	-35.64%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-175.9M
EPS	$-3.70
FCF per share	$-3.00
Financing cash flow	$262.2M
Free cash flow	$-147.9M
Free cash flow minus SBC	$-167M
Investing cash flow	$-72.3M
Net cash flow	$41.9M
Net income	$-164.2M
Operating cash flow minus SBC	$-167M
Operating income	$-175.9M
Stock-based compensation	$19.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$7.59
Debt / equity	0
Long-term assets	$545,000
Long-term liabilities	$33,000
Net cash (debt)	$372.8M
Net cash / market cap	48.65%
Net cash growth	58.23%
Net debt / equity	-1.02
Piotroski F-Score	2
Property, plant and equipment	$370,000
Shareholders' equity	$366.8M
Tangible book value	$366.8M
Tangible book value per share	$7.59
Total assets	$394.7M
Total cash	$373.1M
Total debt	$351,000
Total liabilities	$27.9M
WACC	11.67%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$394.2M
Current liabilities	$27.8M
Current ratio	14.16
Net working capital	$-6.5M
Quick ratio	13.4
Working capital	$366.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-30.39%
Dividend yield	0%
Shareholder yield	-30.39%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$28.36
1D price change	2.4%
1M price change	-45.59%
1M total return	-45.59%
1W price change	-17.88%
1W total return	-17.88%
1Y price change	-20.57%
1Y return CAGR	-20.59%
1Y total return	-20.57%
20-day SMA	$18.78
200-day SMA	$27.02
3M price change	-48.67%
3M total return	-48.67%
50-day SMA	$25.32
50-day SMA vs 200-day SMA	50under200
52-week high	$35.83
52-week high date	2026-06-26
52-week low	$11.36
52-week low date	2026-10-06
6M price change	-48.96%
6M total return	-48.96%
All-time high	$36.37
All-time high date	2024-11-08
All-time low	$11.36
All-time low date	2026-10-06
Average true range (ATR)	$1.93
Average volume	2.6M
Beta (1Y)	1.18
Beta (2Y)	1.24
Beta (5Y)	1.35
Change from 52-week high	-55.99%
Change from 52-week low	38.82%
Change from all-time high	-57.44%
Change from all-time low	36.27%
Change from open	2.74%
Day's gap	-0.32%
Dollar volume	$12.6M
High price	$15.87
Low price	$15.35
Monthly RSI	38.6
Open price	$15.35
Position in 52-week range	80.77%
Premarket change	3.9%
Premarket close	$15.40
Premarket price	$16.00
Premarket volume	1.6K
Previous close	$15.40
Price vs 150-day SMA	-45.41%
Price vs 20-day SMA	-17.58%
Price vs 200-day SMA	-42.71%
Price vs 50-day SMA	-38.85%
Relative volume	0.31
Return from IPO open	-35.25%
Return from IPO price	-13.67%
RSI	32.58
Sharpe ratio	0.13
Sortino ratio	0.23
Volume	800.6K
Weekly RSI	31.48
YTD price change	-23.06%
YTD total return	-23.06%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	29.6M
Float percentage	60.1%
Shares change (QoQ)	5.63%
Shares change (YoY)	30.39%
Shares held by insiders	1.82%
Shares held by institutions	66.81%
Shares outstanding	49.3M
Short % of float	28.52%
Short % of shares	17.14%
Short ratio	13.5 days

Deeper analysis on AVBP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AVBP report

Is a complete AVBP research report available?

No complete published report is available for ArriVent BioPharma, Inc. (AVBP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ArriVent BioPharma, Inc. (AVBP)

Price

Financial snapshot

Fair-value bridge

Latest news · AVBP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AVBP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AVBP

Frequently asked questions